Context Therapeutics Inc.

CNTX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001842952


None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $68.5M
Warnings	thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Mar 23, 2026 239 days before the rescan; latest periodic filing 10-Q received Nov 10, 2026
Last close	$0.17 2026-11-16; market equity $15.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 23, 2026

We are a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies ("bsAb") for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 ("CLDN6") x CD3 TCE, CT-95, a Mesothelin ("MSLN") x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 ("Nectin-4") x CD3 TCE. CTIM-76 is a CLDN6 x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. IND-enabling studies on CTIM-76 have been completed.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 36.0						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						
Accruals ratio	(11.7%)	(6.7%)		36.0	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 22.6						
Altman Z double-prime	3.57	0.31		23.7	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
interest expense must exceed $100,000						
Current ratio	8.52x	2.68x		21.4	781	2025-12-31
Growth and financing, sleeve percentile 26.8						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	11.1%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	33.9%				
one or more required annual facts are missing						
Asset growth, three years	21.7%	3.2%		19.3	663	2025-12-31
Net share issuance, one year	2.4%	1.6%		34.2	624	2026-03-19

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(72.4%)	(1.7%)	7
Distance from 52-week high	(95.1%)	(31.5%)	2
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(173.3%)	0.5%	4
Book value to price	2.03	0.28	94
Sales to price	not computable	0.36	
Composite equity issuance, five years	not computable	13.2%	
Relative strength against the sector, log excess return	(1.46)	(0.19)	7
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$34.4M
Operating cash flow, four quarters	-$34.0M
Months of runway	12.2
Days since last periodic filing	7 (10-Q received Nov 10, 2026)
Median daily dollar volume, 63 sessions	$336,948

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$36.1M	2025-12-31	2026-03-23	10-K	26-020498
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$26.4M	2025-12-31	2026-03-23	10-K	26-020498
3	assets	us-gaap:Assets	$68.5M	2025-12-31	2026-03-23	10-K	26-020498
4	assets	us-gaap:Assets	$98.1M	2024-12-31	2026-03-23	10-K	26-020498
5	current assets	us-gaap:AssetsCurrent	$68.4M	2025-12-31	2026-03-23	10-K	26-020498
6	current liabilities	us-gaap:LiabilitiesCurrent	$8.0M	2025-12-31	2026-03-23	10-K	26-020498
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$130.9M	2025-12-31	2026-03-23	10-K	26-020498
8	operating income	us-gaap:OperatingIncomeLoss	-$39.7M	2025-12-31	2026-03-23	10-K	26-020498
9	book equity	us-gaap:StockholdersEquity	$60.5M	2025-12-31	2026-03-23	10-K	26-020498
10	liabilities	us-gaap:Liabilities	$8.0M	2025-12-31	2026-03-23	10-K	26-020498
11	operating income	us-gaap:OperatingIncomeLoss	-$10.5M	2021-12-31	2023-03-22	10-K	23-000041
12	interest expense	us-gaap:InterestExpense	$64,240	2021-12-31	2022-03-23	10-K	22-000029
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$33,948	2025-12-31	2026-03-23	10-K	26-020498
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$14.6M	2024-12-31	2026-03-23	10-K	26-020498
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$7,316	2024-12-31	2026-03-23	10-K	26-020498
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$21.0M	2023-12-31	2025-03-20	10-K	25-000028
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2023-12-31	2025-03-20	10-K	25-000028
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$13.5M	2022-12-31	2024-03-21	10-K	24-000011
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$36,836	2022-12-31	2024-03-21	10-K	24-000011
20	assets	us-gaap:Assets	$16.1M	2023-12-31	2025-03-20	10-K	25-000028
21	assets	us-gaap:Assets	$38.0M	2022-12-31	2024-03-21	10-K	24-000011
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	91,879,177	2026-03-19	2026-03-23	10-K	26-020498
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	89,704,194	2025-03-18	2025-03-20	10-K	25-000028

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.